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ABSTRACT: Continuous high-frequency DBS is an
established treatment for essential tremor and Parkin-
son’s disease. Current developments focus on trying to
widen the therapeutic window of DBS. Adaptive DBS
(aDBS), where stimulation is dynamically controlled by
feedback from biomarkers of pathological brain circuit
activity, is one such development. Relevant biomarkers
may be central, such as local field potential activity, or
peripheral, such as inertial tremor data. Moreover, stim-
ulation may be directed by the amplitude or the phase
(timing) of the biomarker signal. In this review, we
evaluate existing aDBS studies as proof-of-principle,
discuss their limitations, most of which stem from their
acute nature, and propose what is needed to take
aDBS into a chronic setting. VC 2017 The Authors.
Movement Disorders published by Wiley Periodicals,
Inc. on behalf of International Parkinson and Movement
Disorder Society
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Deep brain stimulation (DBS) has become an established
and reversible treatment of motor symptoms in essential
tremor, dystonia, and severe Parkinson’s disease (PD),
resulting in reductions in clinical impairment and
increased quality of life in patients.1-7 The DBS systems
used in current clinical practice effectively operate open-
loop so that stimulation parameters remain constant over
time between visits to the clinician. With few exceptions,
stimulation is applied at regular and high frequencies, in
excess of 100 Hz. Such high frequencies of stimulation are
believed to create an acute information lesion, whereby
transmission of aberrant neural activity is attenuated.8-10
At the same time, however, any residual physiological
communication may be impaired in the stimulated brain
circuit.11 It is perhaps no surprise then that the application
of DBS in movement disorder patients is limited by side
effects such as speech impairment, psychiatric symptoms,
and antagonistic worsening in some motor functions,
which are all thought to arise from interactions between
the stimulation and local brain circuits.11-16 Such side
effects could potentially be reduced by sparing neural cir-
cuits from high-frequency stimulation when dysfunction is
limited or by patterning stimulation so that it is far more
selective for dysfunctional neural dynamics. In line with
this, recent studies suggest that DBS might be more effi-
cient and efficacious if modulated in response to the
inferred state of activity in pathological brain circuits.17,18
The primary goal of DBS that adapts to the current
state of pathological activity, so called adaptive DBS
(aDBS), is to increase the specificity of the interven-
tion, and thereby widen the therapeutic window. A
secondary goal is to reduce power drains on the
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implanted pulse generator (IPG). Improvements in battery
technology have lessened but not negated the gains to be
had from reduced power consumption. A significant pro-
portion of patients are unsuitable for rechargeable IPG sys-
tems,19 and those that are would benefit from the ability to
recharge less frequently. However, perhaps the most excit-
ing impact of reduced power demands might be the possi-
bility of reducing rechargeable battery size sufficiently to
enable skull mounted IPGs.20-22
How might aDBS systems infer the current state of
activity in the pathological circuits with which they
interact? Essentially information can be derived from
peripheral measures of motor state, such as the moni-
toring of tremor or involuntary writhing movements
(dyskinesias), directly from recordings of brain activ-
ity, or through a combination of these approaches.
Where deep brain signals are recorded these must be
robust over many years, and for this reason local field
potential activity is preferred over microelectrode
recordings of neurons, even though features of both
may correlate with symptoms.23-27 Microelectrode
recordings are, however, less stable over time. Also
critical is to consider the nature of those pathological
circuits in which activity is inferred. These may be
mechanistically or causally related to the symptoms or
serve as faithful markers of the primary circuit dys-
function. In the former case, stimulation can be specif-
ically patterned to maximally disrupt the underlying
causal circuit dynamics, as for example, in the case of
phase-responsive forms of stimulation being pioneered
for the treatment of tremor.28 In the latter case, the
DBS intervention is necessarily more generic, and its
delivery is controlled by the inferred state of the
unmeasured or unknown primary circuit dysfunction.
An example of a generic DBS approach is the stereo-
typed high-frequency stimulation that forms conven-
tional DBS (cDBS). This may be modulated according
to the amplitude of signals that need not directly
relate to the primary circuit dysfunction, but provide
indirect evidence of the severity of the latter. We term
this amplitude-responsive aDBS and distinguish it
from the more specific phase-responsive DBS currently
being developed for tremor treatment (Fig. 1). An
example of amplitude-responsive aDBS is DBS which
is delivered according to the level of beta (13-30 Hz)
local field potential (LFP) activity recorded in the sub-
thalamic nucleus (STN); we do not know for sure
whether beta activity is causally important or not, but
it correlates with motor impairment in PD patients
undergoing functional neurosurgery29 and thereby
provides a surrogate for whatever may be mechanisti-
cally at play.
The choice between amplitude and phase-responsive
approaches primarily depends on the maturity of our
knowledge about underlying causal circuit dysfunc-
tion. In the case of tremor it is reasonable to attribute
the peripheral disturbance to central oscillators that
empirical evidence suggests can be controlled at the
level of the motor cortex or thalamic cerebellar receiv-
ing areas.30,31 For most conditions, however, we have
no compelling evidence as yet that one or other circuit
feature lies at the heart of the motor disturbance. For
these it is best to use generic high-frequency DBS
and to control its delivery through the monitoring of
surrogates such as the beta activity recorded in the
STN LFP.
In this review, we first consider the evidence moti-
vating further development of amplitude-responsive
and phase-responsive aDBS, the limitations of trials
performed to date, and what remains to be done if
aDBS is to be translated in to clinical practice.
Applications and Supporting
Evidence
Amplitude-responsive aDBS
Amplitude-responsive aDBS was systematically tested
in parkinsonian humans for the first time in an acute
trial in 201317 after a landmark study of aDBS in non-
human primates yielded promising results.32 Unilateral
DBS was performed for about 10 minutes in 8 PD
patients in the STN up to 7 days after electrode implan-
tation. High-frequency DBS was delivered whenever the
beta activity exceeded a threshold amplitude of beta in
the STN. This resulted in a 50% reduction in the contra-
lateral upper limb Unified Parkinson’s Disease Rating
Scale (UPDRS) motor score assessed by blinded evalua-
tion compared to no stimulation. When compared with
cDBS, aDBS was significantly (27% absolute reduction)
more effective and resulted in a 56% reduction in time
on stimulation. An important element of the study was
the comparison of aDBS to random, intermittent stimu-
lation unlocked to LFP bursts of beta activity. Random
DBS resulted in trivial UPDRS change in blinded assess-
ments despite involving almost exactly the same time on
stimulation as aDBS. Hence randomness of stimulation
could not account for the clinical efficacy of aDBS.
Nevertheless, this proof of principle study was lim-
ited by short stimulation times and unilateral applica-
tion that did not allow assessment of axial signs and
gait. These limitations were addressed in a follow-up
study of bilateral aDBS in 4 PD patients tested over
stimulation sessions lasting up to about 2 hours.33 Here
aDBS improved blinded total UPDRS III scores by 43%
when compared with no stimulation, similar to the
improvement in cDBS studies in which blinded video
assessments have been made.34,35 aDBS also resulted in
a 55% reduction in stimulation time, which could be
decreased further by additional administration of levo-
dopa. The bilateral sensing and stimulation and longer
stimulation times in this study enabled the assessment
of gait and axial signs, which presented an
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improvement on the earlier study. However, no direct
comparisons between aDBS and cDBS were made.
An additional animal study trialed amplitude-
responsive DBS of the STN in a single nonhuman pri-
mate MPTP-model of PD.36 The study found aDBS to
be as good, if not better, than cDBS in reducing rigid-
ity despite stimulation being present for only about
50% of the time and that reaching speed was not
changed by either treatment. However, only cDBS
reduced the speed of the return from a reach with the
upper limb in a cue reaching task.
Together these studies suggest that, at least under
acute testing conditions, aDBS is effective despite
involving substantially less energy than cDBS. This
reduction in energy raises the hope that side effects
will be correspondingly less for a given voltage or
current of stimulation than with cDBS and that the
goal of a widened therapeutic window might be met.
Several studies support this hypothesis. Both a case
report and a case series of bilateral aDBS in freely
moving PD patients have used a scalar approach
where stimulation voltages varied according to LFP
beta changes through a personalized algorithm,
rather than the binary approach of turning DBS on
and off used in other studies (Fig. 1B, lower green
panel). aDBS substantially reduced the dyskinesias in
patients on medication.37,38 In addition, the acute
impact of aDBS on speech was assessed in 10 PD
patients in a further study.28 The patients received
bilateral aDBS and cDBS, but only cDBS caused an
acute deterioration in speech, assessed through the
blinded assessment of the speech intelligibility test.
This was despite the better motor improvement with
aDBS in this cohort.
FIG. 1. Schematic summary displaying different forms of DBS. A shows conventional DBS where pulses occur at a constant frequency. B depicts two
forms of amplitude responsive DBS; upper green panel, event-dependent control where stimulation is triggered and terminated when a signal, like beta-
amplitude, rises above and falls below a threshold, respectively and green lower panel, continuous-time control where stimulation varies proportionately
to the amplitude of the signal. C shows phase-responsive DBS where pulses of high-frequency stimulation are timed to a particular phase by either
event-dependent (upper orange panel) or continuous time control (lower orange panel). [Color figure can be viewed at wileyonlinelibrary.com]
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One concern with the use of beta activity as a feed-
back biomarker has been what might happen during
movement, when beta activity is suppressed.36 In prac-
tice this has not been a problem in patient studies, as
much of the motor UPDRS involves active movement,
and yet this is improved during beta amplitude-
responsive aDBS. This might be because bradykinetic
movements are associated with poor beta reactivity so
that impaired movement may still be accompanied by
beta activity that is sufficient to trigger stimulation.39-42
Dopaminergic medication improves both beta reactivity
and movement, but stimulation under these more physi-
ological circumstances is less relevant.
Another issue has been how might amplitude-
responsive aDBS work in PD. This was addressed in a
recent electrophysiological analysis of previously
reported data sets.43 The study showed that aDBS
selectively trims long duration beta bursts and
increases the number of short beta bursts, relative to
no stimulation and cDBS. Critically, the amplitude of
beta bursts scales with their duration so that longer
bursts signal greater pathological oscillatory synchro-
nization within the local neural population. In line
with this, the prevalence of short and long beta bursts
negatively and positively correlated with motor
impairment, respectively.
What about amplitude-responsive DBS for tremor?
Here there have been several trials. These, unlike the
above, have been performed in chronically implanted
patients, although they still remain acute in nature. The
earliest study used not the severity of tremor itself to trig-
ger stimulation onset, but surface electromyographic
(EMG) activity over the deltoid muscle signalling upper
limb activation. This was then used to trigger periods of
thalamic DBS in five patients with severe intention tremor
due to multiple sclerosis, 2 of whom had pronounced
functional benefit.44 However, the absence of a control
condition without stimulation meant that it was unclear
whether benefit was due to lesion effects or adaptive DBS.
Subsequent studies have used the severity of tremor
recorded with peripheral inertial-based sensors and/or sur-
face EMG activity as the feedback signal, a personal com-
puter to process the signals, extract key features and
implement the control algorithm, and electromagnetic
telemetric communication with the IPG. Control algo-
rithms usually involve simple thresholding of processed
signals, but can be more sophisticated, and utilize addi-
tional information about whether the patient is engaged
in rest, posture, or action.45 The nature of the telemetric
link and implanted IPG has meant that stimulation is then
controlled with an approach of turning DBS on and off.
The clinical efficacy of aDBS for tremor can be diffi-
cult to ascertain from these more recent trials, as some
only formally evaluate the success of tremor predic-
tion45 or report changes in tremor amplitude, rather
than changes in clinical rating scales more readily
related to disability. Yamamoto and colleagues46 aimed
to treat intention tremor in patients with severe essen-
tial tremor and triggered high-frequency thalamic DBS
whenever spectral power at tremor frequency in the
EMG from biceps brachii exceeded a customized
threshold. This led to complete resolution of intention
and action tremor, as assessed unblinded using corre-
sponding elements of the essential tremor rating scale in
all 4 patients tested. The average time on stimulation
was not reported, however. Another important trial
explored amplitude-responsive aDBS in tremor-
dominant PD.47 Five patients were studied and unilat-
eral high-frequency DBS was delivered whenever the
tremor power detected by a Smart Watch (LG G-watch)
exceeded a threshold. Tremor power was reduced on
average only by 37% relative to baseline, but this was
achieved with voltages that were almost 80% lower
than those used for cDBS. Stimulation was also deliv-
ered for only 50% of the time. However, the system
had difficulty in distinguishing tremor from episodes of
voluntary movements, and these were therefore
excluded from analysis.
Phase-responsive aDBS
Where we have good reason to suspect that a particu-
lar neural activity directly relates to symptomatology we
can potentially increase the efficiency and selectivity of
electrical stimulation by patterning the latter so that it
specifically modulates the causal neural activity. In a
landmark study from 2011, Rosin and colleagues32 per-
formed a form of phase-responsive aDBS in the MTPT
model of PD in 2 nonhuman primates. They showed
aDBS to be more effective at attenuating motor symp-
toms compared to cDBS when applying brief, high-
frequency bursts of simulation to the globus pallidus
interna, 80 ms after the detection of spikes in single neu-
rons recorded in the ipsilateral M1. The 80-ms delay was
critical in improving motor impairment and corre-
sponded to the cycle of the 9-15 Hz beta band oscilla-
tions typical of this model. Recently, phase-responsive
aDBS has been applied to treat tremor.48 The assumption
here is that oscillatory activity in brain circuits drives
peripheral tremor oscillations with a more or less fixed
time delay, so that delivering DBS pulses at particular
phases of the cycle of the peripheral tremor will also
mean that such stimulation is phase locked (albeit with a
fixed offset) to the pathological neural activity. Dynami-
cal systems theory and empirical data suggest that there
should be phases at which impulses will increase or
decrease the amplitude of the oscillations, just as there
are points in the excursion of a child’s swing at which a
push will impede or increase the swing cycle.49 Phase-
responsive aDBS for tremor aims to selectively stimulate
at those phases that attenuate tremor amplitude. Stimu-
lation consists of bursts of high-frequency pulses timed
to a particular phase of the tremor and delivered to the
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ventrolateral thalamus (Fig. 1C, upper orange panel).
Sustained locking of DBS to the optimal phase for ampli-
tude suppression led to clinically significant tremor relief
in 3 of the 5 patients with essential tremor tested, despite
delivering less than half the energy of conventional high-
frequency stimulation.48
Nevertheless, phase-responsive aDBS has not been
delivered for longer than 30 seconds thus far, and lon-
ger trials are essential. Only then will it be possible to
test whether this form of stimulation will give sus-
tained tremor suppression with an improved side
effect profile due to the lower energy delivery and
selectivity for those oscillations that are phase locked
to the stimulation. In the longer term it will also be
interesting to see if this technique can improve akine-
sia and rigidity when stimulation is phase-locked to
beta activity in the STN.
With regard to parkinsonism, coordinated reset neu-
romodulation, where brief bursts of stimulation pulses
are asynchronously delivered to different parts of the
subthalamic region, has in proof-of-concept studies in
primates and humans shown after effects with beta
LFP suppression and UPDRS score improvements.50,51
This is hypothesized to be a result of neuronal phase
resetting followed by plastic changes in local neural
circuits. These proof-of-concept studies indicate that
DBS phase targeting in PD patients could have rela-
tively sustained symptom-attenuating effects.
In practice the successful application of phase-
responsive aDBS will also entail consideration of how
best to keep pathological oscillators in the
desynchronized state. This is because the amplitude
attenuating effects of aDBS at suppressive phases build
up over many cycles. Phase-responsive aDBS alone
would mean a delay in tremor suppression whenever
significant tremor emerged. In the study by Cagnan
and colleagues48 when phase-responsive aDBS induced
clinically significant tremor suppression it did so over
the course of several seconds in some patients with
essential tremor, but then the weak tremor precluded
reliable identification of tremor phase and effectively
led to random stimulation at low frequency. This
tremor remained suppressed, raising the possibility
that random low-frequency stimulation is sufficient to
keep central tremor oscillators desynchronized once
they have been suppressed.
In summary, phase-responsive aDBS may be best
thought of as a means of suppressing tremor and con-
trolling episodes of break-through tremor, but a neces-
sary adjunct may be intercurrent stimulation to
maintain tremor in its attenuated state. In this regard,
phase-responsive aDBS might be considered similar to
conventional high-frequency DBS in that the acute
effect of both on tremor is delayed, and the clinical
benefits accrue because once tremor is suppressed it is
maintained in this state by continued stimulation. The
major difference is that aDBS may involve lower over-
all frequencies of stimulation and less energy delivery.
Limitations and Roadblocks
Research on aDBS to date raises several issues.
Leveraging Existing Electrode Designs
Currently, aDBS is delivered through standard DBS
electrodes. Until recently, these were exclusively quad-
ripolar, which leads to constraints when brain signals
are recorded through the same electrode and used for
feedback control. This is because the difference in
voltage between stimulation pulses and pathological
LFP activity is so great that common mode rejection is
necessary to recover spontaneous LFP activity. Stimu-
lation therefore has to be delivered at either of the 2
middle contacts of the quadripolar electrodes, and the
LFP recorded bipolarly from the neighboring pair of
contacts. The net result is that fewer electrode con-
tacts are available for aDBS performed in this way
than for cDBS. This, however, may be less of a prob-
lem as the number of electrode contacts increases as
electrode design improves. Octopolar directional and
nondirectional electrodes are already available and
thin-film probe technology has made realistic the pos-
sibility of high density, high resolution, multicontact
DBS electrodes.52
Difficulty in Assessing Efficacy
Trials of aDBS in which feedback is derived from
LFP activity have necessarily been carried out 2 to 7
days after electrode implantation because of the need
to record directly from implanted electrodes. This is
problematic. First and foremost, patients may experi-
ence substantial symptom relief as a result of the so-
called “stun effect” resulting from local trauma,53 and
it is for this reason that most centers delay postopera-
tive programming.54 The exact duration of the stun
effect is not fully established, but recent studies have
found UPDRS score improvements off stimulation
postoperatively compared to the preoperative state for
up to 6 months after electrode placement.53 It has also
been shown that changes in both impedance and LFPs
occur after electrode implantation, particularly within
the first 24 hours.5,55,56 For these reasons, acute peri-
operative aDBS findings may not necessarily be repre-
sentative of the chronic state.
Another disadvantage of studying the effects of aDBS
in the acute postoperative setting is the limited time
available and confounding postoperative fatigue leading
to drifts in baseline performance. Time constraints and
stun effects limit the extent to which cDBS may be
optimized, and this may explain why cDBS fails to
have an appreciable therapeutic effect in some stud-
ies.28,37 This complicates the interpretation of the acute
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perioperative contrast of the performance of aDBS and
cDBS, as neither may be representative of that follow-
ing recurrent optimization in the chronically treated
patient. Some of these limitations could be circum-
vented by contrasting aDBS and cDBS acutely at the
time of battery change. Here stun effects are absent
and the experimenter benefits from the knowledge of
the clinically optimized stimulation parameters.
Difficulty in Assessing Side Effects
Although there have been some encouraging initial
reports of reduced side effects during aDBS, those side
effects seen and tested in the acute postimplantation
period may also be unrepresentative of the chronic
state. Dyskinesias may, for example, be problematic
when stimulation is combined with dopaminergic
medication following surgery, but this will be less so
once the stun effect abates and once medication has
been titrated over time.37 The speech impairment that
was shown with acute cDBS, and was absent with
aDBS, might also disappear with optimisation of cDBS
stimulation site and parameters over time.28 In reality,
side effects (and efficacy) should be assessed during
chronic treatment in the patient’s everyday environ-
ment, with the clinical team afforded the opportunity
to optimize both DBS therapy and medication.
Insufficient Time for Adaptive Effects
The mechanisms by which DBS exerts its therapeutic
effects are still not fully understood and are very likely
multimodal involving various time-dependent mecha-
nisms such as acute local neuromodulation, changes in
synaptic plasticity, and long-term anatomical reorgani-
zation.10 Any potential, adaptive, long-term effects
cannot be studied in the acute setting and will need to
be assessed during chronic treatment. Interestingly, a
tendency for the time on stimulation to progressively
fall during aDBS has been reported, suggestive of
short-term plasticity.17 Such plasticity has also been
noted in computational studies of desynchronizing
brain stimulation, including DBS,57 and may contrib-
ute to the carry-over effects of high-frequency electri-
cal stimulation triggered by automated seizure
detection noted in patients with epilepsy.58
The converse of the above is maladaptive plasticity,
and this is perhaps commonest in the treatment of
essential tremor by conventional thalamic DBS. Here
it leads to habituation to the effects of DBS over time
and gait ataxia,59,60 and prolonged trials are necessary
to determine whether this also occurs with aDBS.
Use of Simplistic Feedback Signals and
Control Algorithms
Hitherto, feedback signals have generally been one
dimensional, such as beta power or tremor severity.
FIG. 2. Improvements in motor scores assessed blinded in the studies of
Little et al. 2013 and Little et al 2015. Data are presented as the mean 6
standard error of the mean percentage change in UPDRS scores.
FIG. 3. Potential Combined Beta-Tremor Control loops. DBS stimulation is triggered whenever one or other or both signals cross independent
thresholds and is terminated whenever both signals have fallen below their thresholds. [Color figure can be viewed at wileyonlinelibrary.com]
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However, this may be suboptimal. For example, beta
power in the STN correlates with bradykinesia and
rigidity, but it does not do so with tremor.18,23 Thus
aDBS systems that rely on beta activity feedback run
the risk of not controlling tremor. So far, in practice,
this has not been the case, perhaps because tremor is
one of the features that is most susceptible to the stun
effect or because the stimulation intensity necessary
for tremor suppression was below that needed for
beta suppression, and bursts of aDBS were given suffi-
ciently frequently for tremor to remain suppressed.
Nevertheless, there is a case to be made for combining
both beta activity and inertial sensor activity in a dual
feedback control loop (Fig. 3). Indeed, there are many
other possible brain and peripheral signals that corre-
late with motor impairment that could, in principle,
be combined for more precise control of different
symptoms.18,61-63
However, the potential use of multiple feedback sig-
nals raises issues of redundancy, sufficiency, and trac-
tability. Is the information from additional signals
redundant? Are the benefits to be had with existing
biomarkers, if borne out with chronic aDBS, sufficient
in offering a step improvement in therapy? Are other
candidate feedback signals tractable and practical in
combination or alone? Consider, for example, the
recording of the STN high-frequency oscillations over
200 to 400 Hz and the modulation of these by the
amplitude of local beta activity (termed phase-ampli-
tude coupling), which have been demonstrated to cor-
relate with bradykinesia and rigidity.64,65 Detecting
the very low amplitude of STN high-frequency oscilla-
tions in the setting of high-frequency stimulation deliv-
ered through the same electrode is likely to be very
difficult and power demanding. An alternative might
be to record phase-amplitude coupling at the level of
the motor cortex,66 but it is unclear whether cortical
high-frequency oscillations are any different in ampli-
tude to those in the STN. On the other hand, recent
work suggests that phase-amplitude coupling may be
at least partly driven by asymmetries in the waveform
of beta band oscillations,67 and in this case there
would certainly be advantages to cortical recordings
as cortical beta is significantly greater in magnitude
than STN beta due to the improved spatio-temporal
integration afforded by cortical lamination.
In addition to the simplicity of current feedback sig-
nals, amplitude-responsive aDBS has most often relied
on an on-off control policy. This is an “event-
dependent control,” whereby the change of state (on/
off) of the stimulation depends on beta amplitude cross-
ing a predefined threshold (Fig. 1B, upper green panel).
Although this can work well, for example, in the ther-
mostatic control of central heating, it ignores informa-
tion that might be afforded by the continuous evolution
of the feedback signal. For example, is room
temperature dropping fast, in which case there might be
an advantage in turning on the central heating earlier or
higher. Continuous evolution of the signal is considered
in continuous-time control strategies (Fig. 1C, lower
green panel). So far the latter have been implemented in
the simple form of the proportional control used by
Rosa and colleagues.37 Here high-frequency stimulation
was controlled so that its intensity depended propor-
tionally (with a constant gain) on the amplitude of beta
activity at all times. An alternative approach would be
to implement proportional-integral-derivative control,
a well-established and successful engineering method,68
recently successfully applied in automated insulin deliv-
ery systems.69 This form of control responds to and
anticipates changes in the feedback signal both rapidly
and efficiently. Moreover, continuous-time control
lends itself to implement more advanced control
approaches such as nonlinear stochastic dynamic con-
trol or multivariable control. A simple example of the
latter would be a dual-control system, whereby central
beta activity and inertial signals related to peripheral
tremor are simultaneously controlled by stimulation, or
different spectral elements of the local field potential
activity are simultaneously controlled but with different
set references. This very versatility of continuous-time
control, however, again underscores the need to con-
sider issues of redundancy, sufficiency and tractability
in aDBS design. Furthermore, it is critical that such
design considers biological constraints. One specific
constraint with respect to DBS is that stimulation effects
have a threshold so that continuous-time control below
this threshold may be relatively superfluous and ineffi-
cient. Accordingly, future implementations of aDBS
may involve hybrid control whereby continuous-time
control approaches kick in once a threshold signal value
is surpassed.
Finally, when considering multidimensional feedback
and more sophisticated control systems it is important
to bear in mind limitations on the embedded computing
power possible in implanted systems and the battery
power burden that these operations may bring.
Amplitude-responsive aDBS has been estimated to
decrease total electrical energy delivered by about
130 mW per side,17 whereas the energy consumed by a
low-energy circuit underpinning a single-channel power
classifier should be no more than about 10 mW. Thus
unidimensional signals and a simple control policy can
achieve very significant energy savings, but this remains
to be seen if more complex approaches are sought.70
Lack of Optimization
Hitherto the threshold of on-off control or the gain
of the proportional control have been determined heu-
ristically. This means that although beneficial, they
may not still be optimal. Indeed, there are multiple
parameters to select and optimize in DBS, including
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contacts to be stimulated, pulse width, stimulation fre-
quency, and stimulation intensity. In amplitude-
responsive DBS additional variables are the frequency-
band of interest and smoothing of the feedback signal,
the threshold, the steepness of any ramp in stimulation
introduced to limit side effects such as paraesthesia,
and the duration of any lock-out period before stimu-
lation can be triggered again. In phase-responsive DBS
additional variables are the selection of the phase for
stimulation, and the number and frequency of pulses
to be delivered at that phase. So far choices have been
made on empirical grounds, but the very presence of
an informative feedback signal offers the possibility
of automatic, on-line, comprehensive optimization of
variables to achieve maximal effect on the feedback
signal—something that is just not feasible to achieve
through clinical assessments.
Need for Patient Selection
With only acute trials performed thus far it is difficult
to predict which patients might respond best to chronic
aDBS. Patient selection is likely to be particularly
important when applying more specific phase-
responsive techniques. Indeed, in the study by Cagnan
and colleagues,48 only patients with essential rather
than dystonic tremor had the potential for marked
tremor suppression, and even within those with essen-
tial tremor there were factors such as tight tuning of
tremor and the presence of a single dominant limb oscil-
lation that favored a good response. Broadening phase-
responsive stimulation to those with more than 1 pat-
tern of limb oscillation over time may require systems
that can track the principal tremor axes characterizing
independent oscillators and optimize the phase of stim-
ulation accordingly.
Questions About Long-term Stability
What if the feedback features and the thresholds or
gearings used in aDBS change over time, with medica-
tion changes, alteration in the brain–electrode interface,
or disease progression? At present this question is
totally unexplored, as aDBS has only been acutely tri-
aled. However, for aDBS to be clinically useful it must
be robust to changes over time and may need the func-
tionality to perform auto-identification and auto-tuning
so that the system can identify online and in real-time
optimal control parameters. As a minimum, it may be
necessary to include a system that monitors the stability
of the control loop. Such a system could, for instance,
be implemented in a simple way by using a performance
index such as the Integral Time-weighted Absolute
error, which can be performed with very little comput-
ing power.68 This would enable a fail-safe approach
whereby should the performance index exceed a given
value, aDBS could be reverted to cDBS; then when the
performance index returns to a suitable value, the aDBS
algorithm would be reactivated.
Conclusion: The Implantable
Technology Gap
Adaptive DBS is a promising therapeutic develop-
ment that may, in time, complement other innovative
approaches to deep brain stimulation, such as novel
pulse parameters or current steering.63 The hope, too,
is that it might eventually be rolled out to movement
disorders other than parkinsonism and tremor, as
knowledge of correlating biomarkers or causal neural
patterns matures. Phase-responsive aDBS might also
lend itself to the control of some of the intractable
childhood epilepsy syndromes characterized by long
and rhythmic sequences of epileptic activity. However,
the aDBS studies performed to date have significant
limitations, and these stem from the fact that the
investigations have all necessarily been acute, either
because the only way to reliably record low-amplitude
subcortical LFPs and to rapidly react to changes is to
externalize electrode connections in the short-lived
perioperative window or because electromagnetic
telemetry links to chronically implanted IPGs are
slow, sensitive to alignment, and unsuitable for
chronic trials in real-life situations. We are therefore
fast approaching an impasse in which the utility and
chronic viability of aDBS cannot be further explored
without suitably functioning, implantable, medical
grade devices. Overcoming this roadblock will require
the continued development of permissive technology
by the medical devices industry.
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